M20 Genomics, also known as 杭州跃真生物科技有限公司, is a leading life sciences company specializing in the development of single-cell products and related technologies. Established in February 2021, M20 has quickly gained recognition in the field with its groundbreaking advancements in single-cell sequencing. The company's flagship product, M20 Seq, is the world's first high-throughput single-cell full-length transcriptome sequencing technology based on random priming.

This breakthrough innovation enables researchers to achieve high-throughput single-cell transcriptome sequencing across all species and sample types. M20 Genomics is comprised of a team of renowned experts from top universities worldwide, including Zhejiang University, Harvard University, MIT, Duke University, Peking University, UC Berkeley, and the National University of Singapore. Their extensive research and application experience in single-cell sequencing have led to globally leading scientific and translational achievements.

Since its inception, M20 has received significant investments from top venture capital firms, including Sequoia Capital and Qiming Venture Partners, reflecting the company's rapid growth and potential. Partnering with established industry leaders, M20 has established the Next Generation Single Cell technology (NGSC) ecosystem, offering collaboration opportunities with companies such as Annoroad, LC Sciences, BGI Genomics, Majorbio, Berry Genomics, and more. M20 Genomics is committed to pushing the boundaries of scientific exploration and revolutionizing disease diagnostics and therapeutics through cutting-edge single-cell technologies.

With a wide range of applications and a strong focus on research and development, M20 is positioned as a leader in the single-cell sequencing platform. For more information about M20 Genomics and their products, you can visit their website at www. m20genomics.

com or contact their hotline at 400-909-6060